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Abstract
BACKGROUND—Change from nonmolecular to molecular testing techniques is thought to
contribute to the increasing trend in incidence of Clostridium difficile infection (CDI); however
the degree of effect attributed to this versus other time-related epidemiologic factors is unclear.
METHODS—We compared the relative change in incidence rate (IRR) of healthcare facility–
associated (HCFA) CDI among hospitals in the Duke Infection Control Outreach Network before
and after the date of switch from nonmolecular tests to polymerase chain reaction (PCR) using
prospectively collected surveillance data from July 2009 to December 2011. Data from 10
hospitals that switched and 22 control hospitals were included. Individual hospital estimates were
determined using Poisson regression. We used an interrupted time series approach to develop a
Poisson mixed-effects model. Additional regression adjustments were made for clustering and
proportion of intensive care unit patient-days. The variable for PCR was treated as a fixed effect;
other modeled variables were random effects.
RESULTS—For those hospitals that switched to PCR, mean incidence rate of HCFA CDI before
the switch was 6.0 CDIs per 10,000 patient-days compared with 9.6 CDIs per 10,000 patient-days
after the switch. Estimates of hospital-specific IRR that compared after the switch with before the
switch ranged from 0.89 (95% confidence interval [CI], 0.32–2.44) to 6.91 (95% CI, 1.12–42.54).
After adjustment in the mixed-effects model, the overall IRR comparing CDI incidence after the
switch to before the switch was 1.56 (95% CI, 1.28–1.90). Time-trend variables did not reach
statistical significance.
CONCLUSION—Hospitals that switched from nonmolecular to molecular tests experienced an
approximate 56% increase in the rate of HCFA CDI after testing change.
Clostridium difficile infection (CDI) is a major healthcare-associated pathogen that causes
significant morbidity and mortality, increased length of stay, and increased hospitalization
costs.1-3 Thus, CDI is a logical target for surveillance and prevention efforts at the national,
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state, and individual hospital levels. Multiple studies that included surveillance data up to
2009 have reported that the incidence of healthcare-associated CDI was increasing.4-8 For
example, the incidence of CDI increased in our network of community hospitals; in fact,
CDI overtook methicillin-resistant Staphylococcus aureus as the most common cause of
hospital-acquired infection.9 Multiple theories and explanations exist for the increasing CDI
trend in North America.4,10 The emergence and spread of the highly toxigenic BI/NAP1/027
clone is credited with causing a surge of infections.10-13 In addition, widespread use of
broad-spectrum and quinolone antibiotics may be driving the increase in this clearly
antibiotic-associated illness.14,15 Finally, the growing number of elderly individuals residing
in chronic care facilities represents a population at particularly high risk for CDI.16
Several other factors, however, may be introducing a surveillance bias into interpretations of
longitudinal trends. For example, definitions that capture community-onset healthcare
facility–associated (CO-HCFA) CDI were introduced in 2008, which may have improved
our ability to recognize CDI cases that occur after discharge from acute care hospitals.6,17
Also, increasing awareness and focus on CDI may alert clinicians to perform testing for CDI
in a larger number of at-risk patients. Finally, increased sensitivity of molecular diagnostic
tests has improved the laboratory detection of CDI cases.18-20 Thus, the combination of
several of the above factors may affect accurate interpretation of global and local trends
when attempting to assess the success of CDI prevention programs or perform external
benchmarking.
Earlier studies have attempted to quantify the expected increase in the incidence of CDI that
should occur after switching to a molecular diagnostic test. These studies, however, have
primarily used data from a single center, were unable to adjust for time-dependent factors
that may be unrelated to the change in testing, or did not have a control group
comparator.21-24 The purpose of this study, therefore, is to estimate the effect of the switch
from nonmolecular to molecular laboratory diagnostic tests on the incidence of healthcare-
facility associated CDI using time-trended CDI surveillance data from a large sample of
community hospitals while adjusting for time-dependent and other hospital-level factors.
METHODS
Study Design and Setting
We performed a quasiexperimental, interrupted time series analysis of prospectively
collected CDI surveillance data from the Duke Infection Control Outreach Network from
July 1, 2009, to December 31, 2011. DICON is a network of 43 nonteaching community
hospitals in Virginia, North Carolina, South Carolina, Georgia, and Florida that share
infection control resources and services from liaison infection preventionists (IPs) and
physician epidemiologists.25 Membership in the network is voluntary and based on
contractual agreements for consultative, educational, and information technology services.
Decisions to switch CDI testing strategies were based on local hospital policy changes and
not controlled by researchers. Inclusion criteria required all study hospitals to have complete
CDI surveillance data for the duration of the study period. Each hospital performed
laboratory testing according to local policy and procedures with respect to test type, brand,
and whether specimens were sent out to reference laboratories. Each hospital’s clinical
microbiology laboratory performed local validations and quality control for their clinical
specimens as part of routine practice.
This study was approved by the Duke University Medical Center Institutional Review Board
as exempt research. Surveillance data were obtained from a de-identified central database
according to established data use agreements between DICON and each local hospital.
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Centers for Disease Control and Prevention (CDC) National Healthcare Safety Network
(NHSN) surveillance definitions were used to identify incident cases of CO-HCFA and
hospital-onset HCFA CDI.1 Local IPs at each hospital conducted prospective routine
surveillance and microbiology-based manual chart review for use in infection prevention
efforts. The study period corresponds with introduction of the 2008 change in CDC
surveillance definitions for CDI, which included source type interpretations.17 This change
in definition was fully incorporated into routine surveillance and data entry for the DICON
database on July 1, 2009, which was the start of the study period. Recurrent cases were
excluded.
The hospital-level cluster variable was defined using statistical control g-charts that plotted
the date of the HCFA CDI event by the number of days-between infections for each
hospital.26 Cluster-periods were identified during weeks when 5 consecutive time-between-
infection data points occurred below the mean for the time-period or 5 consecutive time-
between-infection data points occurred in a downward trend. Switch hospitals had 2 means
calculated for the time-period before and after the switch to molecular testing to account for
phase change occurring with introduction of the new diagnostic test.
Statistical Analysis
The effect of the switch to molecular testing on incidence rate of HCFA CDI was estimated
by means of Poisson regression using an interrupted time series approach to produce an
incidence rate ratio (IRR) and 95% confidence interval (CI). Each hospital’s time series was
calculated in weeks. Before and after time variables were centered on the date of testing
change for switch hospitals and the final time point for control hospitals. Variable amounts
of postswitch follow-up time were available among switch hospitals. For each week, each
hospital’s data included the number of diagnosed CDI cases, the person-days denominator, a
covariate indicating the percentage of intensive care unit (ICU) patient-days divided by total
patient-days, a binary variable indicating use of polymerase chain reaction (PCR) testing,
and another binary indicator for presence of a hospital-level cluster of infections during that
week.
First, hospital-specific adjusted IRR estimates for each switch hospital were generated by
Poisson regression using only each individual switch hospital’s data. This analysis was
completed to visualize single-hospital experiences, with an understanding that the small
amounts of before and after data would be inadequate for statistically significant results or
hypothesis testing for most single hospitals.
Then, the total time series data for both switch and control hospitals were combined and
analyzed in a multivariate, piecewise, Poisson mixed-effects model.27 The effect of each
random variable was estimated for the entire study period but allowed to vary randomly
within each hospital, accounting for both between- and within-hospital variation. The IRR
estimate measuring the increase in cases attributable to the switch to PCR testing was treated
as a fixed effect that did not vary between hospitals. Variables for time trends were explored
using nonlinear modeling and the examination of the resulting Akaike Information Criterion
for hierarchical models to determine the ideal shape of the time trends. A secondary analysis
estimating the effect of the switch to PCR based on the brand of nonmolecular test used
before the switch was performed using a similar mixed effects model with binary indicator
variables for each nonmolecular test type.
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The study included 10 switch hospitals that changed from nonmolecular tests to PCR and 22
control hospitals that maintained the same nonmolecular diagnostic testing strategy for the
entire study period. Eleven DICON hospitals were excluded because incomplete
surveillance data were reported for the study period. As a result of local policy decisions and
under no control of the researchers, all 10 hospitals that switched to PCR testing used the
Cepheid Xpert C. difficile assay (Xpert CD assay; Cepheid). The study involved a total of
1,805 cases of CDI over 4,038,447 patient-days, 345,671 (8.6%) of which were ICU patient-
days. The median CDI rate per week over the span of the study was 0.00 cases per 10,000
patient-days (interquartile range, 0.00–6.15). The mean (± standard deviation) was 4.36 ±
9.28 cases per 10,000 patient-days, with the rate ranging as high as 190.76 cases per 10,000
patient-days during a week in which there were clustered infections.
Hospital, ICU, and laboratory characteristics for 10 switch hospitals and 22 control hospitals
are described in Table 1. Average bed sizes of switch hospitals were larger than but not
significantly different from those of control hospitals (P = .2). Type of nonmolecular tests
varied among switch and control hospitals and included the following: Premier Toxins A&B
(Meridian Bioscience), Immunocard A&B (Meridian Bioscience), C. difficile Tox A/B II
(TechLab), or C. Diff Quik Check Complete (TechLab). Two hospitals sent specimens out
to reference laboratories for C. difficile testing. Switch hospitals had variable amounts of
follow-up time after the switch in diagnostic testing, ranging from 4 to 117 weeks (Table 2).
Poisson interrupted time series models that used single-hospital data were constructed for
the 10 switch hospitals to observe single-hospital experiences, again with an understanding
that an individual hospitals’ surveillance data were not powered to do hypothesis testing.
The average incidence rate of HCFA CDI before the switch to PCR was 6.0 cases of CDI
per 10,000 patient-days compared with 9.6 cases of CDI per 10,000 patient-days after the
switch for switch hospitals. Adjusted hospital-specific estimates that compared HCFA CDI
rates after to before switch to molecular testing ranged from 0.89 (95% CI, 0.32–2.44) to
6.91 (95% CI, 1.12–42.54; Table 2 and Figure 1). Most (7 of 10) individual switch hospitals
experienced a numerical increase in HCFA CDI rate. Only 2 of 10 switch hospitals
experienced a decrease (Table 2 and Figure 1). A meaningful hospital-specific estimate
could not be calculated for one switch hospital because of the short period of follow-up time
in which there were no reported cases after the switch (hospital 10).
Hospital time series from the 10 switch and 22 control hospitals were combined into a
mixed-effect model that included the same covariates: linear time trends before and after
switch, proportion of ICU patient-days, and a binary indicator for a cluster period. Nonlinear
terms for time trends did not produce any improvement in model fit over linear terms.
Linear time trends were not statistically significant in the adjusted model, which suggests
that the baseline rate of CDI remained stable during the study period. Both the cluster period
indicator and the proportion of ICU-days to total patient-days were strong predictors of
HCFA CDI rate (Table 3). The overall adjusted IRR (aIRR) estimate of the effect of switch
to molecular testing was 1.56 (95% CI, 1.28–1.90; Figure 2).
Secondary analyses that delineated between the brand of nonmolecular tests used before the
switch to PCR revealed minimal differences in the effect of the switch on incidence rate
within the precision allowed by available data. Switch from Premier Toxins A&B
(Meridian) produced an estimated aIRR of 1.57 (95% CI, 1.22–2.03). C. difficile Tox A/B II
(Techlab) produced an aIRR of 1.70 (95% CI, 1.27–2.27). Switch from C. Diff Quik Check
Complete (TechLab) produced an estimated aIRR of 1.16 (95% CI, 0.55–2.49), with limited
precision because only a single switch hospital used this test. An estimate of switch from
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Immunocard A&B (Meridian) to PCR could not be generated because of sparse data from
hospital 10, which only included 4 weeks of data after the switch. Hospital 10 was the only
switch hospital to use this brand of nonmolecular test.
DISCUSSION
Improved test sensitivity because of the change to molecular diagnostic testing can produce
both positive and negative effects. Sensitivity and specificity estimates for Cepheid PCR are
94%–100% and 93%–99%.18 In contrast, sensitivity and specificity estimates for enzyme
immunoassays are 60%–81% and 91%–99% when compared with toxigenic anaerobic
culture.28 However, a molecular test is more expensive to implement, may cause confusion
among ordering providers, and be overused because of its novelty. Also, the more sensitive
test may be “too good” at identifying patients who are colonized but not truly infected with
C. difficile.1 In the context of testing for potentially transmittable diseases within the
hospital setting, the improved sensitivity of molecular tests allows infected and colonized
patients to be rapidly and reliably identified. Infection control measures and active antibiotic
therapy can be instituted without the delays or confusion caused by false-negative testing.
Thus, in theory, molecular tests may more effectively prevent in-hospital transmission of
CDI.
In this study, we demonstrate that changing to the more sensitive molecular test will cause a
significant increase in HCFA CDI incidence rate during the transition year. The average
increase in rate for this study was 56%, which is consistent with earlier estimates. Longtin et
al21 performed parallel testing at a single academic hospital in Canada and reported a 52%
increase in HCFA CDI rate. Goldenberg et al24 also reported a 57% increase in CDI rates at
their hospital in the United Kingdom after switch to a 2-step PCR strategy. Fong et al22
reported a 2.3-times greater prevalence of positive test results after switch with unadjusted
data from the Cleveland Clinic. CDC researchers have also preliminarily reported an effect
size of 59%–89% from 5 hospitals compared with nonswitch control hospitals using
laboratory-identified CDI events.23
At the local level, our estimate can be used to gauge how much of an increase in rate may be
expected with the testing switch during the transition year. Infection prevention teams using
this estimate must still consider other concomitant causal factors that may require their
attention and effective interventions. Importantly, the variability of the effect in each
individual hospital’s experience should be noted. In fact, 2 hospitals in our study saw a
numerical decrease in their incidence rates after the switch. Therefore, the degree of
uncertainty around our estimate should be considered when interpreting local, unadjusted
data in which multiple factors may be at play.
Another important finding of this study was the lack of statistically significant time trends in
the incidence of HCFA CDI after adjustment for the switch to molecular testing. Although
many sources, including our group, have described increasing CDI incidence in the United
States in the last 10 years, more recent surveillance trends have not yet been widely
reported.29 Billing data suggest that the CDI uptrend may be slowing or leveling off in
2009–2010,30 which would be consistent with the current study findings. Perhaps this
observed stable trend may be attributable to ongoing awareness of CDI and infection
prevention efforts. Another potential explanation may be that our 2.5-year study period was
not long enough to detect a larger, gradual, longitudinal trend. In an exploratory analysis of
our data, linear time trend variables for the 32 hospitals did not become statistically
significant when regression adjustment for switch to PCR testing was withheld (data not
shown). However, it is conceivable that, in larger data sets or those covering a longer period,
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simply reporting surveillance data without accounting for differences in testing sensitivity
may have conversely led to the conclusion that rates were still increasing.
Important limitations to this study must be noted. This is a nonrandomized, retrospective
quasi-experimental study with limited adjustment for potential unmeasured confounding
factors, such as antibiotic use, changes in infection prevention practices, and patient case
mix. We believe that the statistically significant predictor of ICU-days per total patient-days
is a crude but reasonable proxy for case mix. This factor, however, has not previously been
considered, to our knowledge, in risk-adjustment methods for multihospital CDI data.31
Another important case mix covariate to consider would be advanced age; however, we did
not have this variable measured in our prospectively collected CDI surveillance data.
Second, because of the availability of before and after data, there were variable amounts of
data for switch hospitals after the change in testing. This affected the precision of our
hospital-specific estimates, although every hospital contributed to the estimation of time
trends and precision of the mixed model regardless of switch date. Third, the realignment of
time centered on the testing switch date may have avoided our discovery of distinct seasonal
or week-to-week time trends. However, the intent of our interrupted time series approach
was to account for the larger, global increasing trend in CDI that has been previously
described. Thus, we feel that our strategy for adjustment for clustering and inclusion of
nonswitch hospital data in calculating the baseline trend was adequate for this purpose.
Finally, our study included a network of smaller-sized community hospitals in the
southeastern United States and may not be generalizable to other practice settings,
particularly academic, tertiary care hospitals. Despite the above, our study uses data from 32
hospitals, includes hospitals that did not switch testing methods as comparators in
determining temporal trends, and describes the varied experiences at individual institutions
that implemented the molecular testing switch.
In the era of publicly reported data for hospital-acquired infections, changing to a superiorly
sensitive diagnostic test may lead to inaccurate assessments of the quality of an infection
prevention program. We agree with several authors who have called for recognition of
surveillance bias in interpretation of externally benchmarked data for interhospital
comparison when heterogeneous diagnostic testing strategies are used.21,22,24,29,32
Accordingly, we now stratify hospitals by diagnostic testing strategy to provide separate
benchmarks for member hospitals in DICON that use molecular tests for C. difficile. The
CDC NHSN is also moving toward using molecular testing as a factor in the risk adjustment
strategy for laboratory-identified events.29,31 More importantly, however, epidemiologists
must consider that a shift in diagnostic testing strategy introduces a surveillance bias when
assessing local, national, and regional trends over time and the public health impact of C.
difficile infection. Our study results provide a reasonable estimate that can be used when
interpreting trends in local CDI data after implementing a molecular diagnostic test.
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Hospital-specific estimates of the effect of switching from nonmolecular to polymerase
chain reaction diagnostic testing on incidence rate of healthcare facility–associated
Clostridium difficile infection. The Y-axis is on the logarithmic scale. Hospital 10 is not
included because of the lack of data after switching to create a hospital-specific estimate
with interpretable precision. IRR, incidence rate ratio.
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Multivariate mixed model estimate of effect of switch from nonmolecular to polymerase
chain reaction diagnostic testing on incidence rate of healthcare facility–associated
Clostridium difficile infection, Duke Infection Control Outreach Network, 2009–2011.
Model adjustment variables were held constant assuming no clusters of infection and 9%
intensive care unit–days per total patient-days. CI, confidence interval; PCR, polymerase
chain reaction.
Moehring et al. Page 10

























Moehring et al. Page 11
TABLE 1
Hospital and Clostridium difficile Diagnostic Test Characteristics, Duke Infection Control Outreach Network,
2009–2011
Variable PCR switch hospitals (n = 10) Control hospitals (n = 22)
Bed size, mean no. of beds (±SD) 280 ± 126 230 ± 160
Nonmolecular test type (manufacturer)
 Premier Toxins A&B (Meridian) 4 (40) 2 (9)
 C. Diff Quik Check Complete (TechLab) 4 (40) 6 (27)
 C. difficile Tox A/B II (TechLab) 1 (10) 5 (23)
 Immunocard A&B (Meridian) 1 (10) 9 (41)
Specimens sent out to reference laboratory 1 (10) 2 (9)
Proportion ICU-days per total patient-days, mean % (±SD) 8 ± 3 10 ± 4
Mean no. of weeks with clusters (±SD) 2 ± 3 3 ± 3
NOTE. Nonmolecular test type for switch hospitals was the testing brand used before the switch. All hospitals switched to Cepheid PCR. Data are
no. (%) of hospitals, unless otherwise indicated. ICU, intensive care unit; PCR, polymerase chain reaction; SD, standard deviation.
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TABLE 2
Hospital-Specific Estimates of Effect of Switch from Nonmolecular to Polymerase Chain Reaction Diagnostic
Testing on Incidence Rate of Healthcare Facility–Associated Clostridium difficile Infection
Hospital no. Time before switch, weeks Time after switch, weeks aIRR (95% CI)
1 118 13 3.35 (1.46–7.72)
2 102 29 1.20 (0.64–2.26)
3 82 49 3.39 (1.08–10.63)
4 98 33 2.79 (0.62–12.68)
5 75 56 1.55 (0.95–2.51)
6 83 48 1.71 (0.47–6.15)
7 14 117 6.91 (1.12–42.54)
8 102 29 0.65 (0.26–1.59)
9 77 54 0.89 (0.32–2.44)
10a 127 4 …
NOTE. aIRR, adjusted incidence rate ratio. All estimates were adjusted for the following covariates: linear time before switch, linear time after
switch, binary cluster indicator, and intensive care unit–days per total patient days expressed as a percentage.
a
Hospital 10 did not have enough data after switch to create a hospital-specific estimate with interpretable precision.
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TABLE 3
Multivariate Mixed Effects Interrupted Time Series Model of Effect of Switch from Nonmolecular to
Polymerase Chain Reaction Diagnostic Testing on Incidence Rate of Healthcare Facility–Associated
Clostridium difficile Infection
Mixed-effects model variable Fixed or random effect aIRR (95% CI) P
PCR switch Fixed 1.56 (1.28–1.90) <.001
Time before switch Random 1.00 (1.00–1.00) .5
Time after switch Random 1.00 (1.00–1.00) .8
Cluster Random 3.88 (3.00–5.01) <.001
ICU-days per total patient-daysa Random 1.02 (1.01–1.02) <.001
NOTE. aIRR, adjusted incidence rate ratio; ICU, intensive care unit; PCR, polymerase chain reaction.
a
Expressed as a percentage.
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